At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 111 enrolled
Drug / intervention
Emibetuzumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib
In Brief
A Phase 2 clinical trial evaluating Emibetuzumab and Erlotinib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 111 participants across 59 sites in 10 countries.
Detailed Summary
The primary purpose of this study is to evaluate the efficacy of the study drug known as LY2875358, administered alone or in combination with a second drug named Erlotinib, in participants affected by a defined type of lung cancer (MET biomarker diagnostic positive Non-Small-Cell Lung Cancer) that experienced a disease progression during the most recent treatment with Erlotinib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesBelgium, France, Germany, Israel, Italy, Netherlands, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartAug 2013
Primary CompletionFeb 2015
Study CompletionMar 2016
TodayJul 2026
First PostedJul 16, 2013
Enrollment StartAug 1, 2013
Primary CompletionFeb 1, 2015
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.0 years ago
Interventions
Emibetuzumabdrug
Administered IV
Erlotinibdrug
Administered Orally